在"现实世界"中的患者结果与在关键AML试验中研究的患者群体有多相似?
Ing Soo Tiong1,2,3, Meaghan Wall3,4, Ashish Bajel1,5,6
1Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Blood cancer journal
|March 27, 2024
概括
急性髓性白血病 (AML) 的现实结果与临床试验数据不同,影响了新疗法评估. 不同的数据集对于考虑到地理治疗差异和确保准确评估新的AML药物至关重要.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 临床试验 临床试验
背景情况:
- 历史患者队伍越来越多地被认为是药物开发中的合成控制武器.
- 然而,现实世界结果与临床试验结果的可比性存在有限的数据.
- 癌症注册表往往缺乏详细的治疗方法和进行可靠比较所需的分子数据.
研究的目的:
- 将急性髓性白血病 (AML) 患者的现实结果与最近批准的疗法临床试验中的结果进行比较.
- 确定现实数据和临床试验人群之间的治疗和结果的关键差异.
- 强调各种数据集在评估新型AML疗法的重要性.
主要方法:
- 利用了澳大利亚白血病和淋巴瘤组国家血液癌症注册表 (ALLG NBCR) (2012-2018) 中942名AML患者的数据.
- 将注册表数据与已发表的随机试验中的年龄和疾病匹配的对照和干预人群进行了比较.
- 包括中素,吉姆图祖马布臭胺,CPX-351,口服阿扎西提丁和venetoclax的试验.
主要成果:
- 与临床试验人群相比,观察到现实世界结果的显著差异.
- 观察到的antracycline类型,cytarabine强度/调度以及全源造血细胞移植频率的变化.
- 现实世界结果显示与一些研究相比,但与其他研究有显著差异.
结论:
- 与AML的临床试验数据相比,现实世界的数据呈现出不同的模式.
- 治疗方案和移植实践的差异影响了结果.
- 对各种数据集的彻底评估,考虑到地理差异,对于使用历史数据评估新型AML疗法至关重要.
相关概念视频
01:20Comparing the Survival Analysis of Two or More Groups
181
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
181
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
126
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
126
01:24Kaplan-Meier Approach
136
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
136
01:21Cancer Survival Analysis
345
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
345
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K